Jazz PharmaceuticalsJAZZ.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Jazz Pharmaceuticals (JAZZ.O) trades at a P/E of 14.50x, P/B of 2.85x, P/S of 2.97x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 16th percentile over the trailing 10Y window (vs. 21st percentile over 3Y); P/B sits at the 65th percentile over the trailing 10Y window (vs. 83rd percentile over 3Y); P/S sits at the 48th percentile over the trailing 10Y window (vs. 85th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 23rd percentile within its industry and the 37th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.92%, ranking at the 56th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 49.7 points — relying on either metric alone could be misleading. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Jazz Pharmaceuticals operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: JAZZ · JAZZ
Want the full picture on whether Jazz Pharmaceuticals (JAZZ.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 14.50 | ||||||
| P/B (MRQ) | 2.85 | ||||||
| P/S (TTM) | 2.97 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.92% |